BioLife Solutions (NASDAQ:BLFS) (NASDAQ:BLFS) is a leading developer and manufacturer of biopreservation media and automated thawing instruments designed to support the cell and gene therapy, regenerative medicine, and biobanking markets. The company’s products are engineered to protect living cells during storage, transportation, and preparation for clinical or research applications. Its core offerings include proprietary cryopreservation formulations—such as CryoStor® and HypoThermosol®—and ThawSTAR® automated thawing systems, which help standardize and streamline critical bioprocessing steps.
Founded in 1995 and headquartered in Bothell, Washington, BioLife Solutions has grown from a small startup into a global supplier serving pharmaceutical manufacturers, academic research centers, contract development and manufacturing organizations, and cell therapy developers. The company operates manufacturing facilities in North America and Europe, and it has established a network of distributors and partnerships that extend its reach to Asia Pacific and other key biotech hubs. These regional operations are backed by quality systems compliant with FDA and EMA regulations.
Over its history, BioLife Solutions has built a robust intellectual property portfolio covering biopreservation media compositions and thawing technologies. The company collaborates closely with industry leaders to validate its products in a range of cell therapy platforms, including CAR-T, NK cell, gene-edited stem cell, and tissue regeneration therapies. BioLife’s solutions are integrated into both preclinical research workflows and late-stage clinical and commercial manufacturing processes.
Under the leadership of President and CEO James Miceli, BioLife Solutions continues to invest in research and development to enhance product performance and expand its offering of single-use systems and on-demand services. With a focus on quality, regulatory support, and customer training, the company aims to drive consistency and efficiency in biopreservation workflows, helping clients advance critical therapies from the lab bench to the patient.
